The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The impact of cost savings on treatment decisions and policy changes in AML
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, comments on the impact of cost savings on treatment decisions and policy changes in acute myeloid leukemia (AML). Dr Desai highlights that while cost is not the primary consideration when selecting treatment, it could influence policy decisions regarding patients who may be eligible for both intensive and lower-intensity regimens. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I don’t think that we would obviously choose a regimen because of the cost savings, but what it would impact in terms of policy is, you know, there are going to be considerations where some patients who are intensive chemo-eligible may be eligible for both intensive and lower-intensity regimens. And depending on biology, depending on ongoing trials, there may be decisions that are made in the future where intensive chemo-eligible patients might be considered for lower-intensity regimens...
So I don’t think that we would obviously choose a regimen because of the cost savings, but what it would impact in terms of policy is, you know, there are going to be considerations where some patients who are intensive chemo-eligible may be eligible for both intensive and lower-intensity regimens. And depending on biology, depending on ongoing trials, there may be decisions that are made in the future where intensive chemo-eligible patients might be considered for lower-intensity regimens. And this is important to know because of these analyses that if that were to happen, there are advantages beyond the remission and survival. There are advantages to lower ER visits, less time in hospitalization, and cost savings. Obviously, this is not the reason to give lower-intensity regimens, but if they were to be equivalent, and that is considered, this is something that could be used by, you know, even policymakers or insurance reimbursement that this regimen would lead to cost savings as long as it is either comparable or potentially better than intensive chemo, depending on what we will find in the future with the randomized trials that are currently ongoing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
